Mesentech Inc.
Vancouver · British Columbia, Canada corporation · 3 known investors
Mesentech develops prostaglandin prodrugs aimed at musculoskeletal regeneration. The company operates in the biotechnology and drug development space.
Also known as Mesentech
Founders & leadership
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$3.9M disclosed across 1 round · 2022
▶$3.9MraisedApr 2022 · 21 investors · BiotechnologyRule 506(b)
- Barbara YanniDirector
- Samuel WuDirector
- David HymanExecutive Officer
- Robert Norman YoungExecutive Officer, Director
- Jay MohrDirector
- David DvorakDirector
- Jonathan PolakExecutive Officer, Director, Promoter
- Offering amount
- $7M
- Amount sold
- $3.9M
- First sale
- Mar 2022
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Mesentech Inc. is a Vancouver, British Columbia biotechnology company developing bi-specific small-molecule therapeutics that are selective for both a tissue target and a molecular target. Its conjugate prodrugs link a high-affinity bone-targeting moiety to an active payload so that the drug distributes to bone and releases active species locally, with the stated aim of increasing efficacy while limiting systemic exposure and associated side effects. The company's core focus is prostaglandin (EP4 receptor agonist) prodrugs for musculoskeletal regeneration.
The lead program, MES-1007, is a bone-targeted prodrug of a prostaglandin mimetic intended to reverse bone loss in conditions such as Duchenne muscular dystrophy and osteoporosis; as of late 2020 it was undergoing safety evaluations to enable human studies. Published preclinical work reported improvements in bone density and geometry in a mouse model of severe osteogenesis imperfecta. A clinical-stage bone-targeted EP4 receptor agonist prodrug, MES1022, entered a randomized, double-blind, placebo-controlled first-in-human trial, with first participants dosed as reported in September 2023. A preclinical bone-selective oncology small-molecule conjugate is also described, and the broader pipeline has been characterized as including programs in myelofibrosis, brittle bone disease and cancer. Stated application areas span osteoporosis, cancers, myelofibrosis, infections, bone implant integration and fracture repair, as well as muscular dystrophies.
Founding story
The company was founded by Dr. Robert Young, who previously led medicinal chemistry at Merck, where he led teams associated with the discovery of Singulair, Vioxx, Arcoxia and odanacatib. Gust lists a founding date of November 2013.
Business model
Mesentech operates as a virtual company, with primary research conducted at Simon Fraser University and the University of British Columbia and with in-licensed intellectual property; patents covering the conjugate chemistry are owned by SFU and licensed to Mesentech. It pursues partnership-based collaborations for translational evaluation, preclinical testing and IP licensing, and is funded through equity investment including venture philanthropy.
Traction
Reported milestones include granted US, European and Canadian patents on the conjugate chemistry, peer-reviewed publications on the design, synthesis, pharmacokinetics and biodistribution of bone-targeting EP4 agonist prodrugs and on MES-1007 efficacy in severe osteogenesis imperfecta, a BIO Startup Stadium win in 2020, venture philanthropy investment in 2020, and progression of MES1022 into a first-in-human randomized, double-blind, placebo-controlled trial dosed in 2023.
Latest developments
In September 2023 Mesentech announced successful dosing of the first human participants in a randomized, double-blind, placebo-controlled clinical trial of MES1022, its bone-targeted EP4 receptor agonist prodrug. In June 2022 Rosy Hu of Morningside joined the board of directors.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Mesentech positions itself in bone-targeted drug delivery and regenerative medicine, noting that no approved therapies exist for bone wastage in individuals affected by Duchenne muscular dystrophy and describing dental and orthopaedic implant bone generation as multibillion-dollar markets.
The bi-specific conjugate design targets both a tissue (bone) and a molecular target, intended to deliver the active agent selectively to bone and reduce side effects from systemic exposure, distinguishing it from untargeted systemic administration of prostaglandin agonists.
Technology
The platform uses bisphosphonate-mediated bone targeting combined with prodrug and linker chemistry to create conjugates that bind bone mineral and release an active payload locally over days. Payloads described include EP4 receptor agonists (prostaglandin mimetics), hormones and anti-cancer agents. Supporting capabilities include medicinal chemistry and small-molecule synthesis, radiolabeled pharmacokinetics and biodistribution studies, microcomputed tomography, histology and back-scattered electron microscopy, three-point-bending biomechanical testing, in vivo rodent and rabbit bone models, GLP non-human primate toxicology and IND-enabling studies, and early-phase (Phase I) clinical development.
Go-to-market
The company advances its programs through collaborative preclinical research, licensing agreements and engagement with accelerators and external research platforms, working with disease-focused nonprofits such as CureDuchenne, which took an active role in advancing the prodrug platform for Duchenne and placed its chief scientific officer on Mesentech's scientific advisory board.
Patients with bone and muscle disorders, including pediatric osteoporosis associated with Duchenne muscular dystrophy, osteogenesis imperfecta, osteoporosis, bone cancers and myelofibrosis; the initially stated commercial target market is bone generation for dental and orthopaedic implants. Pharmaceutical and research partners are the counterparties for collaboration and licensing.
Geography
Headquartered in Vancouver, British Columbia, Canada, with an address at 2222 Health Sciences Mall and research conducted at Simon Fraser University and the University of British Columbia.
History
Patents underpinning the technology were granted progressively: a US patent (US9650414B1) covering EP4 conjugate compounds in May 2017, European patent EP2576575B1 on prostaglandin-bisphosphonate conjugates in September 2018, and a Canadian patent covering conjugate drugs in March 2021, all owned by Simon Fraser University and licensed to Mesentech. The company won BIO's Startup Stadium competition at the BIO International Convention in June 2020, received investment from CureDuchenne Ventures and the Charles H. Hood Foundation in November 2020, added Rosy Hu of Morningside to its board in June 2022, and reported dosing of the first human participants in a placebo-controlled trial of MES1022 in September 2023.
Risks & controversies
The company is early stage with a small team and a product portfolio in development; the lead asset only reached first-in-human dosing in 2023, and key intellectual property is licensed from Simon Fraser University rather than owned outright.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 2
by search overlap
Companies competing with Mesentech Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 7
launches, deals, and filingsMesentech announced successful dosing of the first human participants in a randomized, double-blind, placebo-controlled clinical trial of MES1022.
Canadian Intellectual Property Office granted IP covering new chemical entities for bone-targeting conjugate drugs, with expiration in 2031.
CureDuchenne Ventures announced an investment in Mesentech as part of a joint funding collaboration with the Charles H. Hood Foundation, supporting the lead program MES-1007 into clinical development and its evaluation in Duchenne muscular dystrophy. CureDuchenne's chief scientific officer Michael Kelly joined Mesentech's scientific advisory board.
European patent covering prostaglandin-bisphosphonate conjugate compounds, methods of making and uses; owned by Simon Fraser University and licensed to Mesentech.
US patent covering new classes of dual-function bone-targeting EP4 conjugate prodrugs granted; owned by Simon Fraser University and licensed to Mesentech.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structure▸Research sources · 6
primary sources listed
- Mesentech Inc.mesentech.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Mesentech Inc. do?
- Vancouver biotech developing bone-targeted prostaglandin prodrugs for musculoskeletal regeneration.
- Who are Mesentech Inc.'s investors?
- Mesentech Inc.'s investors include 7G BioVentures, Beresford Ventures, WUTIF Capital.
- How much funding has Mesentech Inc. raised?
- Mesentech Inc. has disclosed $3.9M raised across 1 round.
- Where is Mesentech Inc. headquartered?
- Mesentech Inc. is headquartered in Vancouver.